CN113784971A - 一种egfr抑制剂的晶型及其制备方法 - Google Patents

一种egfr抑制剂的晶型及其制备方法 Download PDF

Info

Publication number
CN113784971A
CN113784971A CN202080027663.6A CN202080027663A CN113784971A CN 113784971 A CN113784971 A CN 113784971A CN 202080027663 A CN202080027663 A CN 202080027663A CN 113784971 A CN113784971 A CN 113784971A
Authority
CN
China
Prior art keywords
degrees
compound
formula
crystal form
minus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080027663.6A
Other languages
English (en)
Other versions
CN113784971B (zh
Inventor
刘希乐
张路
丁照中
陈曙辉
胡利红
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medshine Discovery Inc
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN113784971A publication Critical patent/CN113784971A/zh
Application granted granted Critical
Publication of CN113784971B publication Critical patent/CN113784971B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

本发明公开了一种EGFR抑制剂的晶型及其制备方法，还包括所述晶型在制备治疗非小细胞肺癌药物中的应用，尤其是在制备治疗非小细胞肺癌脑转移药物中的应用。
Figure DDA0003295583220000011

Description

PCT国内申请，说明书已公开。

Claims (24)

  1. PCT国内申请，权利要求书已公开。
CN202080027663.6A 2019-04-10 2020-04-10 一种egfr抑制剂的晶型及其制备方法 Active CN113784971B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910285738X 2019-04-10
CN201910285738 2019-04-10
PCT/CN2020/084286 WO2020207483A1 (zh) 2019-04-10 2020-04-10 一种egfr抑制剂的晶型及其制备方法

Publications (2)

Publication Number Publication Date
CN113784971A true CN113784971A (zh) 2021-12-10
CN113784971B CN113784971B (zh) 2023-07-14

Family

ID=72750814

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080027663.6A Active CN113784971B (zh) 2019-04-10 2020-04-10 一种egfr抑制剂的晶型及其制备方法

Country Status (5)

Country Link
US (1) US20220194959A1 (zh)
EP (1) EP3954693A4 (zh)
JP (1) JP7324862B2 (zh)
CN (1) CN113784971B (zh)
WO (1) WO2020207483A1 (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103172641A (zh) * 2011-12-20 2013-06-26 钱卫 杂环胺基烷氧基取代的喹唑啉衍生物及其用途
WO2018143315A1 (ja) * 2017-02-02 2018-08-09 アステラス製薬株式会社 キナゾリン化合物
CN108640928A (zh) * 2016-12-30 2018-10-12 南京明德新药研发股份有限公司 作为egfr抑制剂的喹唑啉类化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020007219A1 (zh) 2018-07-02 2020-01-09 南京明德新药研发有限公司 一种egfr抑制剂的晶型及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103172641A (zh) * 2011-12-20 2013-06-26 钱卫 杂环胺基烷氧基取代的喹唑啉衍生物及其用途
CN108640928A (zh) * 2016-12-30 2018-10-12 南京明德新药研发股份有限公司 作为egfr抑制剂的喹唑啉类化合物
WO2018143315A1 (ja) * 2017-02-02 2018-08-09 アステラス製薬株式会社 キナゾリン化合物

Also Published As

Publication number Publication date
CN113784971B (zh) 2023-07-14
JP7324862B2 (ja) 2023-08-10
EP3954693A1 (en) 2022-02-16
US20220194959A1 (en) 2022-06-23
EP3954693A4 (en) 2022-08-10
JP2022527619A (ja) 2022-06-02
WO2020207483A1 (zh) 2020-10-15

Similar Documents

Publication Publication Date Title
CN107955019B (zh) 一种egfr抑制剂的盐型、晶型及其制备方法
WO2017107985A1 (zh) 喹唑啉衍生物的晶体及其制备方法
WO2022237815A1 (en) Novel forms of Compound I and use thereof
EP3805229B1 (en) Salt of fused ring pyrimidine compound, crystal form thereof and preparation method therefor and use thereof
US20210261546A1 (en) Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof
WO2020007219A1 (zh) 一种egfr抑制剂的晶型及其制备方法
CN113784971B (zh) 一种egfr抑制剂的晶型及其制备方法
CN110467637B (zh) 一种含有氧化膦类取代苯胺的双氨基氯代嘧啶类化合物、制备方法及其应用
CN116768856A (zh) 一种取代的氨基六元氮杂环类化合物的盐及其晶型、制备方法和应用
WO2022063229A1 (zh) 含芳氨基喹唑啉的化合物的盐及其制备方法和应用
CN112004801B (zh) 一种c-MET抑制剂的晶型及其盐型和制备方法
US20220177475A1 (en) Fgfr inhibitor compound in solid form and preparation method therefor
CN116437915A (zh) 一种吡咯并杂环类衍生物的晶型及其制备方法
CN114075135B (zh) 含邻氨基吡啶炔基的化合物的盐及其制备方法和应用
CN108314657A (zh) 一种喹唑啉类抗肿瘤药物中间体的合成方法
CN108299419B (zh) 一种新型egfr激酶抑制剂的几种新晶型及其制备方法
WO2023040863A1 (zh) 嘧啶衍生物及其药学上可接受的盐的多晶型物和应用
CN112159392B (zh) 取代嘧啶化合物及其药物组合物和该化合物的用途
US20240182466A1 (en) A Crystal Form of a Fluorine-substituted Pyridopyrazole Compound and a Preparation Method Thereof
CN111848677B (zh) 一种alk激酶抑制剂化合物的晶型、制备方法及应用
CN111148747B (zh) 吡啶并嘧啶类化合物的盐型和晶型及其制备方法
WO2019010619A1 (zh) 2-(2,4,5-取代苯胺)嘧啶衍生物
WO2023093859A1 (zh) Axl激酶抑制剂的盐、其制备方法和用途
CN116574100A (zh) 一种吡啶并嘧啶酮类化合物的柠檬酸一盐的新晶型及其制备方法与应用
CN114075135A (zh) 含邻氨基吡啶炔基的化合物的盐及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40063054

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant